We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance about adverse possession of registered land. Aimed at conveyancers (practice guide 4).
Explainer for the pharmaceutical industry on the implementation of the Veterinary Medicines Regulation relating to Pharmacovigilance.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
Guidance on adverse possession where a right to be registered was acquired before 13 October 2003 (practice guide 5).
How investigators and sponsors should manage clinical trials during COVID-19
Device-specific guidance for manufacturers on reporting adverse incidents under the vigilance system
Find out if a claim of ownership by adverse possession can be made on common land and town or village greens, what effect it will have on the land and whether a claim can be opposed.
This was a observational study, using data collected at all multidrug-resistant-TB treatment centres in Nigeria
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Chapter 9, section 1 of the immigration directorate instructions deals with whether an adverse decision on an application is justified.
For manufacturers reporting adverse incidents with IVC filters under the vigilance system.
For manufacturers reporting adverse incidents with neurostimulators under the vigilance system.
More information following our investigation into an increase of adverse event reports following the cascade use of intravenous co-amoxiclav (amoxicillin and clavulanic acid) products.
For manufacturers reporting adverse incidents with intraocular lenses under the vigilance system.
Form ST2: Statement of truth in support of an application based upon adverse possession of a rentcharge.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).